274.9712
341.4886
1
1 Lakh
Investment Grown to₹ 10000
Monthly SIP Grown toSuitability:
This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.
We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in flexi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.
But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.
Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.
Taxability of earnings:
Capital gains
Dividends
Please wait...
Please wait...
| YTD | 1-Day | 1-W | 1-M | 3-M | 6-M | 1-Y | 3-Y | 5-Y | 7-Y | 10-Y | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nippon India Pharma Direct-G | -10.18 | -0.05 | 0.00 | 2.70 | 3.21 | 0.04 | -8.53 | 27.73 | 19.28 | 10.32 | -- |
| S&P BSE Healthcare TRI | -10.85 | -0.21 | -0.20 | 2.85 | 2.43 | -2.14 | -10.75 | 23.80 | 13.18 | 4.45 | -- |
| Equity: Sectoral-Pharma | -9.74 | -0.28 | -0.51 | 1.92 | 3.13 | -0.99 | -8.56 | 26.77 | 16.15 | 7.82 | -- |
| Rank within category | 7 | 1 | 2 | 2 | 6 | 1 | 5 | 4 | 1 | 1 | -- |
| Number of funds in category | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 4 | 3 | 0 |
As on 18-Aug-2022
| Fund name | Rating | Launch Date | 1-Year Return | 3-Year Return | 5-Year Return | Expense Ratio | Assets (Cr) |
|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund - Direct Plan | Jan-13 | -8.53 | 27.73 | 19.28 | 1.06 | 4,620 | |
| ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund - Direct Plan | Invest Now | Jul-18 | -8.17 | 27.84 | -- | 1.22 | 2,503 | |
| Mirae Asset Healthcare Fund - Direct Plan | Invest Online | Jul-18 | -6.00 | 31.89 | -- | 0.62 | 1,738 | |
| SBI Healthcare Opportunities Fund - Direct Plan | Invest Online | Jan-13 | -6.27 | 26.88 | 13.66 | 1.07 | 1,668 | |
| DSP Healthcare Fund - Direct Plan | Nov-18 | -9.05 | 30.55 | -- | 0.81 | 1,196 |
| Best Performance | Worst Performance | |||
|---|---|---|---|---|
| Return (%) | Period | Return (%) | Period | |
| Week | 21.40 | 01-Apr-2020 - 09-Apr-2020 | -12.21 | 05-Mar-2020 - 12-Mar-2020 |
| Month | 38.63 | 23-Mar-2020 - 22-Apr-2020 | -21.01 | 20-Feb-2020 - 23-Mar-2020 |
| Quarter | 47.66 | 23-Mar-2020 - 22-Jun-2020 | -14.04 | 29-Dec-2015 - 29-Mar-2016 |
| Year | 90.70 | 23-Mar-2020 - 23-Mar-2021 | -15.12 | 08-Sep-2016 - 08-Sep-2017 |
| Mean | Std Dev | Sharpe | Sortino | Beta | Alpha | |
|---|---|---|---|---|---|---|
| Nippon India Pharma Direct-G | 25.93 | 21.00 | 1.07 | 2.05 | 0.92 | 4.70 |
| S&P BSE Healthcare TRI | 22.78 | 22.44 | 0.86 | 1.63 | -- | -- |
| Equity: Sectoral-Pharma | 25.22 | 20.50 | 1.06 | 2.09 | 0.89 | 4.52 |
| Rank within category | 4 | 6 | 5 | 5 | 6 | 4 |
| Number of funds in category | 9 | 9 | 9 | 9 | 9 | 9 |
The Risk Measures have been calculated using calendar month returns for the last three years.
As on 31-Jul-2022
Please wait...
| Number of Stocks | 27 |
| Top 10 Stocks (%) | 70.26 |
| Top 5 Stocks (%) | 44.85 |
| Top 3 Sectors (%) | 99.34 |
| Portfolio P/B Ratio | 4.26 |
| Portfolio P/E Ratio | 29.75 |
| Fund | Category | |
|---|---|---|
| Average Mkt Cap (Rs Cr) | 41,371 | 56,506 |
| Giant (%) | 15.01 | 20.17 |
| Large (%) | 32.90 | 35.87 |
| Mid (%) | 43.89 | 36.51 |
| Small (%) | 8.20 | 7.35 |
| Tiny (%) | -- | 0.54 |
Please wait...
Indicates an increase or decrease or no change in holding since last portfolio
Indicates a new holding since last portfolio
As on 31-Jul-2022
— Sailesh Raj Bhan since 01-Jan-2013
Education: Mr. Bhan is an MBA (Finance) and CFA.
Experience: Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.
Funds Managed:
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
| Min. Investment (₹) | 5,000 |
| Min. Addl Investment (₹) | 1,000 |
| Min. SIP Investment (₹) | 1,000 |
| Min. No of Cheques | 6 |
| Min. Withdrawal (₹) | 100 |
| Min. Balance (₹) | 1 |
| Lock-in Period | Not Applicable |
| Exit Load | 1% for redemption within 30 days |
| Fund House: | Nippon India Mutual Fund |
| Launch Date: | 01-Jan-2013 |
| Return Since Launch: | 16.49% |
| Benchmark: | S&P BSE Healthcare TRI |
| Riskometer: | Very High |
| Type: | Open-ended |
| Assets: | ₹ 4,620 Cr (As on 31-Jul-2022) |
| Expense Ratio: | 1.06% (As on 31-Jul-2022) |
| Risk Grade: | -- |
| Return Grade: | -- |
| Turnover: | 28.00% |
| Plan | Record Date | Dividend (₹ / Unit) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDCW | 25-Feb-2022 | 3.5000 | |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||
Registrar & Transfer Agent: KFin Technologies Ltd.
Address: 303, Vamsee Estates, Opp. Big Bazaar, Ameerpet, Hyderabad - 500016
Phone: 040-44857874
Email: [email protected]
Website: www.karvymfs.com
You have reserved a spot
Fri, 19-Aug-2022
12:30 PM - 12:40 PM